Researchers at the European Molecular Biology Laboratory (EMBL) have identified sequences in human proteins that might be used by SARS-CoV-2 to infect cells.
LenioBio and Fraunhofer Institute IME have entered a licensing agreement, allowing LenioBio to commercialize technology into a protein expression platform.
